Published in Prog Neuropsychopharmacol Biol Psychiatry on April 26, 2012
Ischemic stroke after use of the synthetic marijuana "spice". Neurology (2013) 4.16
Hemorrhagic stroke following use of the synthetic marijuana "spice". Neurology (2015) 1.43
Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos (2012) 1.41
Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl) (2013) 1.31
Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? Life Sci (2013) 1.28
The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev (2013) 1.26
Gone to Pot - A Review of the Association between Cannabis and Psychosis. Front Psychiatry (2014) 1.14
Baths salts, spice, and related designer drugs: the science behind the headlines. J Neurosci (2014) 1.14
Driving under the influence of synthetic cannabinoids ("Spice"): a case series. Int J Legal Med (2013) 0.99
K2--not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report. J Med Toxicol (2015) 0.98
Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy. J Pharmacol Exp Ther (2013) 0.95
Marijuana: current concepts(†). Front Public Health (2013) 0.95
Synthetic Cannabinoids: Use and Predictors in a Community Sample of Young Adults. Subst Abus (2014) 0.89
In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection. Pharmacol Biochem Behav (2014) 0.89
Spice/K2 synthetic marijuana-induced toxic hepatitis treated with N-acetylcysteine. Am J Case Rep (2014) 0.87
In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22. AAPS J (2016) 0.86
Fascination and Social Togetherness-Discussions about Spice Smoking on a Swedish Internet Forum. Subst Abuse (2013) 0.84
Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry (2016) 0.82
High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J Med Toxicol (2013) 0.82
Marijuana, Spice 'herbal high', and early neural development: implications for rescheduling and legalization. Drug Test Anal (2012) 0.81
Novel psychoactive substance use by US adolescents: Characteristics associated with use of synthetic cannabinoids and synthetic cathinones. Drug Alcohol Rev (2015) 0.81
Synthetic marijuana and acute kidney injury: an unforeseen association. Clin Kidney J (2013) 0.81
Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates. Drug Alcohol Depend (2014) 0.79
Synthetic cannabinoids: the multi-organ failure and metabolic derangements associated with getting high. J Community Hosp Intern Med Perspect (2015) 0.79
Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. Bioanalysis (2014) 0.79
A case of ischemic stroke after bonzai: syntetic cannabinoid from Turkey. Neurol Sci (2015) 0.79
K2 and Spice use among a cohort of college students in southeast region of the USA. Am J Drug Alcohol Abuse (2015) 0.78
Rapid analysis of synthetic cannabinoids using a miniature mass spectrometer with ambient ionization capability. Talanta (2015) 0.78
Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays. J Cheminform (2014) 0.78
Sulfaphenazole and α-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice. Drug Metab Lett (2013) 0.78
The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation. Perspect Medicin Chem (2016) 0.77
Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes. Forensic Toxicol (2016) 0.76
Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid 'Spice' compounds: comparison with Δ(9) -tetrahydrocannabinol. Addict Biol (2016) 0.76
Self-Administration of an Endogenous Cannabinoid 2-Arachidonoylglycerol in Experimentally Naïve Rats. J Alcohol Drug Depend (2015) 0.75
Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites. Curr Top Behav Neurosci (2016) 0.75
Synthetic Cannabinoid Use and Descriptive Norms among Collegiate Student-Athletes. J Psychoactive Drugs (2016) 0.75
In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). Forensic Toxicol (2016) 0.75
A novel psychoactive substance poses a new challenge in the management of paranoid schizophrenia. BMJ Case Rep (2015) 0.75
A 'spicy' encephalopathy: synthetic cannabinoids as cause of encephalopathy and seizure. Crit Care (2014) 0.75
Examination of YouTube videos related to synthetic cannabinoids. Int J Adolesc Med Health (2016) 0.75
Clinical characteristics of synthetic cannabinoid-induced psychosis in relation to schizophrenia: a single-center cross-sectional analysis of concurrently hospitalized patients. Neuropsychiatr Dis Treat (2016) 0.75
Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice. Subst Abuse (2017) 0.75
Synthetic Cannabis Overdose and Withdrawal in a Young Adult: A Case Report, Commentary on Regulation, and Review of the Literature. Case Rep Psychiatry (2016) 0.75
Self-Administration of JWH-018 A Synthetic Cannabinoid in Experimentally Naïve Rats. J Alcohol Drug Depend (2015) 0.75
Analytically Confirmed Intoxications Involving MDMB-CHMICA from the STRIDA Project. J Med Toxicol (2016) 0.75
Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies. Psychopharmacology (Berl) (2016) 0.75
Persistency of Cannabis Use Predicts Violence following Acute Psychiatric Discharge. Front Psychiatry (2017) 0.75
Synthetic Cannabinoid Use Among High School Seniors. Pediatrics (2017) 0.75
Motor vehicle collisions caused by the 'super-strength' synthetic cannabinoids, MAM-2201, 5F-PB-22, 5F-AB-PINACA, 5F-AMB and 5F-ADB in Japan experienced from 2012 to 2014. Forensic Toxicol (2017) 0.75
Synthetic Cannabinoids Use in Elderly Patients. J Psychiatr Pract (2017) 0.75
The effects of synthetic cannabinoids on executive function. Psychopharmacology (Berl) (2017) 0.75
Synthetic cannabinoids found in "spice" products alter body temperature and cardiovascular parameters in conscious male rats. Drug Alcohol Depend (2017) 0.75
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron (2005) 10.49
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ (2002) 3.06
Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol (2006) 2.98
Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Arztebl Int (2009) 2.94
'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom (2009) 2.86
The hippocampal formation in schizophrenia. Am J Psychiatry (2010) 2.82
"Spice" girls: synthetic cannabinoid intoxication. J Emerg Med (2010) 2.76
The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res (2010) 2.45
Beyond THC: The New Generation of Cannabinoid Designer Drugs. Front Behav Neurosci (2011) 2.31
The effects of cannabinoids on the brain. Prog Neurobiol (1999) 2.29
Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett (2010) 2.24
Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom (2010) 2.19
Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics (2011) 2.12
Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci (2006) 2.07
A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend (2011) 2.05
Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr Med Chem (2005) 1.99
Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther (1998) 1.97
Spice: a never ending story? Forensic Sci Int (2009) 1.96
Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry (2008) 1.95
Brain cannabinoid CB₂ receptors modulate cocaine's actions in mice. Nat Neurosci (2011) 1.88
JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol (2010) 1.79
Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One (2011) 1.69
Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci (2006) 1.66
Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry (2010) 1.66
Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in "herbal high" products. J Anal Toxicol (2010) 1.65
Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci Int (2010) 1.60
Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 1.58
Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila) (2011) 1.56
Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med (2011) 1.55
College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy (2011) 1.51
Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor. Mol Pharmacol (2009) 1.47
Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids (2002) 1.46
The "new" marijuana. Ann Pharmacother (2011) 1.45
Delta 9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci Biobehav Rev (1992) 1.45
Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem (2011) 1.45
Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J Mass Spectrom (2011) 1.42
Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends Pharmacol Sci (2007) 1.42
Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv (2011) 1.38
Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci (2009) 1.37
Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther (2009) 1.36
Three cases of "spice" exposure. Clin Toxicol (Phila) (2011) 1.34
Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol (2012) 1.32
Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend (2011) 1.32
Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction (2010) 1.30
JWH-018 and JWH-073: Δ⁹-tetrahydrocannabinol-like discriminative stimulus effects in monkeys. J Pharmacol Exp Ther (2011) 1.28
Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol (2011) 1.27
Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Anal Chem (2011) 1.27
Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol Immunol (2006) 1.26
Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One (2008) 1.26
Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int (2010) 1.25
Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat Protoc (2006) 1.24
The emergence and analysis of synthetic cannabinoids. Drug Test Anal (2011) 1.22
Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med (2006) 1.22
CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin Immunol (2006) 1.20
Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology (2009) 1.20
Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem Phys Lipids (2002) 1.18
Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice. Eur J Pharmacol (2009) 1.18
Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test Anal (2010) 1.18
1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice. Drug Alcohol Depend (2011) 1.18
Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res (2002) 1.17
Designer drugs: a medicinal chemistry perspective. Ann N Y Acad Sci (2011) 1.17
Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis (2011) 1.16
Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 1.15
How globalization and market innovation challenge how we think about and respond to drug use: 'Spice' a case study. Addiction (2010) 1.15
Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem (1992) 1.13
Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci (2008) 1.12
mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci (2008) 1.12
Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry (2011) 1.11
Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos (2011) 1.11
CB2 receptor ligands. Mini Rev Med Chem (2005) 1.11
Intoxication from smoking "spice". Ann Emerg Med (2011) 1.06
"Legal highs" - new players in the old drama. Curr Drug Abuse Rev (2011) 1.04
Synthetic cannabinoid use: a case series of adolescents. J Adolesc Health (2011) 1.03
Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int J Neuropsychopharmacol (2005) 1.03
Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2. Br J Cancer (2009) 1.03
Acute inferior myocardial infarction due to cannabis smoking in a young man. J Cardiovasc Med (Hagerstown) (2009) 1.02
Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology (1995) 1.02
Legal highs on the Internet. Subst Use Misuse (2010) 1.02
Gas and liquid chromatography-mass spectrometry studies on the metabolism of the synthetic phenylacetylindole cannabimimetic JWH-250, the psychoactive component of smoking mixtures. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 1.01
Liquid chromatography-tandem mass spectrometry analysis of urine specimens for K2 (JWH-018) metabolites. J Anal Toxicol (2011) 1.00
Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol (2012) 1.00
Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand (2011) 0.98
Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PLoS One (2011) 0.97
The role of cannabinoids in modulating emotional and non-emotional memory processes in the hippocampus. Front Behav Neurosci (2011) 0.96
Pharmacological specificity of delta 9-tetrahydrocannabinol discrimination in rats. Psychopharmacology (Berl) (1995) 0.95
Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. J Med Chem (1995) 0.95
Comparison of "herbal highs" composition. Anal Bioanal Chem (2011) 0.93
The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. Cereb Cortex (2001) 0.93
Drugs on the web; the Psychonaut 2002 EU project. Prog Neuropsychopharmacol Biol Psychiatry (2006) 0.92
A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem Res Toxicol (2012) 0.90
Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol (2012) 0.90
Synthetic cannabinoids in oral fluid. J Anal Toxicol (2011) 0.90
Detection of synthetic cannabinoids in herbal incense products. Clin Biochem (2011) 0.89
Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels. J Neurosci Res (2001) 0.88
Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.88
Direct screening of herbal blends for new synthetic cannabinoids by MALDI-TOF MS. J Mass Spectrom (2012) 0.87
Detection and identification of the new potential synthetic cannabinoids 1-pentyl-3-(2-iodobenzoyl)indole and 1-pentyl-3-(1-adamantoyl)indole in seized bulk powders in Hungary. Forensic Sci Int (2011) 0.86
Identification of 1-butyl-3-(1-(4-methyl)naphthoyl)indole in a herbal mixture. Forensic Sci Int (2011) 0.83
Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One (2011) 1.69
Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem (2011) 1.45
Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos (2012) 1.41
Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv (2011) 1.38
Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol (2012) 1.32
Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther (2008) 1.29
Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Anal Chem (2011) 1.27
Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int (2013) 1.16
Not simply synthetic tetrahydrocannabinol. J Pediatr (2013) 1.12
Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos (2011) 1.11
Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport (2006) 1.09
CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. Br J Pharmacol (2004) 1.08
Peroxisome proliferator-activated receptors-alpha modulate dopamine cell activity through nicotinic receptors. Biol Psychiatry (2010) 1.05
Nicotinic alpha 7 receptors as a new target for treatment of cannabis abuse. J Neurosci (2007) 1.04
Plasma concentration of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans. Am J Clin Nutr (2010) 1.04
Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther (2007) 1.01
Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. Neuropharmacology (2006) 0.99
The GABAB receptor agonist baclofen prevents heroin-induced reinstatement of heroin-seeking behavior in rats. Neuropharmacology (2007) 0.97
PPARα regulates cholinergic-driven activity of midbrain dopamine neurons via a novel mechanism involving α7 nicotinic acetylcholine receptors. J Neurosci (2013) 0.97
Seizure and coma following Kratom (Mitragynina speciosa Korth) exposure. J Med Toxicol (2010) 0.96
Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos (2009) 0.95
Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol (2013) 0.93
Quantitative measurement of urinary excretion of 3-hydroxyisovaleryl carnitine by LC-MS/MS as an indicator of biotin status in humans. Anal Chem (2010) 0.93
A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem Res Toxicol (2012) 0.90
Urinary excretion of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans. J Nutr (2011) 0.90
Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chem Res Toxicol (2010) 0.90
Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol (2009) 0.90
The suppression of appetite and food consumption by methylphenidate: the moderating effects of gender and weight status in healthy adults. Int J Neuropsychopharmacol (2011) 0.88
K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci (2013) 0.87
Linoleic acid epoxide promotes the maintenance of mitochondrial function and active Na+ transport following hypoxia. Toxicol Lett (2004) 0.86
Urinary excretion of 3-hydroxyisovaleric acid and 3-hydroxyisovaleryl carnitine increases in response to a leucine challenge in marginally biotin-deficient humans. J Nutr (2011) 0.86
Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism. Drug Metab Rev (2010) 0.85
Identification of hydroxywarfarin binding site in human UDP glucuronosyltransferase 1a10: phenylalanine90 is crucial for the glucuronidation of 6- and 7-hydroxywarfarin but not 8-hydroxywarfarin. Drug Metab Dispos (2008) 0.84
Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats. Eur Neuropsychopharmacol (2010) 0.84
Cannabinoid CB1 and Dopamine D1 Receptors Partnership in the Modulation of Emotional Neural Processing. Front Behav Neurosci (2011) 0.81
Molecular mechanisms of cannabinoid addiction. Curr Opin Neurobiol (2013) 0.81
Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther (2011) 0.78
Linoleic acid, cis-epoxyoctadecenoic acids, and dihydroxyoctadecadienoic acids are toxic to Sf-21 cells in the absence of albumin. Toxicol Lett (2002) 0.78
The role of the endocannabinoid system in eating disorders: neurochemical and behavioural preclinical evidence. Curr Pharm Des (2013) 0.78
Targeted metabolomic approach for assessing human synthetic cannabinoid exposure and pharmacology. Anal Chem (2013) 0.78
Quantitative measurement of acetyl fentanyl and acetyl norfentanyl in human urine by LC-MS/MS. Anal Chem (2014) 0.78
Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat. Psychopharmacology (Berl) (2014) 0.77
Marginal biotin deficiency can be induced experimentally in humans using a cost-effective outpatient design. J Nutr (2011) 0.77
Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats. Psychopharmacology (Berl) (2012) 0.77
The ketamine analogue methoxetamine generalizes to ketamine discriminative stimulus in rats. Behav Pharmacol (2016) 0.76
Auricular squamous cell carcinoma. Int J Emerg Med (2011) 0.75
Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects: a review of case reports and preclinical findings. Behav Pharmacol (2016) 0.75
Use of biocytin as neuroanatomic tracer in harvested human pancreas: a confocal laser scanning microscopy analysis. Pancreas (2002) 0.75